Sienna Strengthens its Patent Portfolio


Marking a significant milestone in its commercial growth strategy, Sienna Cancer Diagnostics has added to its intellectual property portfolio for telomerase assay technology, by filing two new provisional patent applications.

The provisional patent applications submitted, cover methods of use patents that help secure Sienna’s exclusivity in the field of telomerase testing for the purpose of clinical diagnostics. Sienna Cancer Diagnostics has already secured a stake in this potentially huge market through the global licensing of key existing patents, as well as having filed a PCT patent application earlier this year.

“Sienna has worked hard to develop the world’s first telomerase based test for use in clinical diagnostics. Securing our first-to-market position with intellectual property protection is key to realising a return on investment for the team’s work. These new provisional patents come at an ideal time in relation to the development of our in-vitro diagnostic product, and solidify our position as market leaders in the field of telomerase based diagnostics”, Sienna’s COO, Matthew Hoskin observed. 


No Very

Captcha Image

Sign up for updates